A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)

Summary

Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be removed with surgery.

In this trial, researchers want to learn if the trial medicine called MK-2010, given alone or with other treatments, can treat advanced solid tumors. MK-2010 is designed to help the immune system fight cancer.

The goals of this trial are to learn:

* About the safety of MK-2010 as monotherapy and in combinations and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems.
* How many participants who receive MK-2010 as monotherapy and in combination respond to treatment. Respond means the cancer gets smaller or goes away.

Conditions

• Malignant Neoplam
• Advanced Solid Tumors

Interventions

BIOLOGICAL

MK-2010

Administered as an intravenous (IV) infusion.

BIOLOGICAL

Pembrolizumab

Administered intravenously as 400 mg every 6 weeks.

DRUG

5-Fluorouracil

Administered intravenously per approved product label.

DRUG

Leucovorin or Levoleucovorin

Administered intravenously per approved product label.

DRUG

Oxaliplatin

Administered intravenously per approved product label.

DRUG

Belzutifan

Administered orally as 120 mg daily.

DRUG

Gemcitabine

Administered intravenously per approved product label.

DRUG

Cisplatin

Administered intravenously per approved product label.

DRUG

Carboplatin

Administered intravenously per approved product label.

DRUG

Paclitaxel

Administered intravenously per approved product label.

DRUG

Nab-paclitaxel

Administered intravenously per approved product label.

DRUG

Pemetrexed

Administered intravenously per approved product label.

DRUG

Epinephrine

Administered per approved product label as rescue medication.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC

  lead INDUSTRY

Principal Investigators

• Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-09-29

Primary Completion

2028-09-26

Completion

2030-07-28

FDA Drug

Yes